FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors

Key Points FVIII-specific IgG antibodies modulate FVIII half-life in patients with hemophilia A, independent of VWF antigen levels and age. Screening for FVIII-specific IgG may be beneficial in tailoring FVIII prophylactic regimens for hemophilia A patients.